Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma

Overview of attention for article published in JAMA Oncology, December 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 16 news outlets
blogs: 1 blog
policy: 1 policy source

twitter: 125 X users
reddit: 1 Redditor
guideline: 1 clinical guideline source

Readers on

mendeley: 43 Mendeley

So far, Altmetric has seen 17 news stories from 16 outlets.

Cabozantinib active, safe for brain metastases in patients with renal cell carcinoma

Healio.com, 27 Dec 2021

December 27, 2021 2 min read Source/Disclosures Published by: Disclosures: Choueiri reports personal fees from AstraZeneca…

Cabozantinib Shows Promise for Renal Cell Carcinoma With Brain Metastases

Neurology Advisor , 30 Nov 2021

Cabozantinib yields promising intracranial activity with an acceptable safety profile for patients who developed brain…

Kabozantynib w leczeniu przerzutów do mózgu u pacjentów z rakiem jasnokomórkowym nerki

Termedia, 23 Nov 2021

Źródło: JAMA Oncology Redaktor: Bogusz Soiński |Data: 23.11.2021 Do analizy retrospektywnej wykorzystano dane pochodzące ze Stanó…

Cabozantinib Yields Promising Intracranial Activity for Renal Cell Carcinoma Brain Metastases

Cancer Network, 16 Nov 2021

Patients who developed brain metastases from renal cell carcinoma experienced promising intracranial activity after being…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 13 additional news stories.